Association of Metabolic Syndrome with Serum Fibroblast Growth Factor 21 in Kidney Transplanted Patients

Overview

Journal J Renal Inj Prev

Specialty Nephrology

Date 2016 Jul 30

PMID 27471739

Citations 4

Authors

Leila Bagheri

Maryam Hami

Mohammad-Javad Mojahedi

Mahin Ghorban Sabbagh

Hosein Ayatollahi

Affiliations

Soon will be listed here.

Abstract

Introduction: Fibroblast growth factor 21 (FGF21) is a metabolic regulator with multiple beneficial effects on glucose and lipid homeostasis and insulin sensitivity.

Objectives: The aim of this study was to investigate the relation between the serum level of FGF21 with and metabolic syndrome (MS) in kidney transplant recipients.

Patients And Methods: We performed a cross-sectional study on 86 stable renal transplant recipients to detect possible relation between serum FGF21 level and MS during October 2014 and Mach 2015. Patients with past history of diabetes mellitus were excluded.

Results: There were 43 patients in each group with and without MS. Totally, they were 52 (60.5%) male and 34 (39.5%) female. The mean age of the MS group was significantly higher than that of non-MS group. There was not significant difference between mean serum creatinine level and glomerular filtration rate (GFR) between two groups (P > 0.05). The MS patients had higher weight and body mass index (BMI) (P < 0.05). The prevalence of BMI >25 kg/m(2) in MS group was 25 (58.8%) versus non-MS group that only 10 (23.3%) had this condition (P < 0.05). The mean of FGF21 level in MS and non-MS groups was 1.23 ± 0.67 ng/l and 1.18 ± 0.71 ng/l, respectively (P > 0.05). There was not significant difference of serum FGF21 level between MS and non-MS patients (P > 0.05).

Conclusion: While the elevated serum FGF21 level was found in subjects with insulin resistant states, however, this study revealed that serum FGF21 levels were not significantly increased in renal transplanted recipients with MS as compared with non-MS group.

Citing Articles

Plasma FGF21 Concentration in Kidney Transplant Patients-Results from Prospective and Cross-Sectional Studies.

Bartmanska M, Wiecek A, Adamczak M J Clin Med. 2024; 13(14).

PMID: 39064306 PMC: 11278288. DOI: 10.3390/jcm13144266.

Fibroblast growth factor 21 may be a strong biomarker for renal outcomes: a meta-analysis.

Yong G, Li L, Hu S Ren Fail. 2023; 45(1):2179336.

PMID: 37009852 PMC: 10071947. DOI: 10.1080/0886022X.2023.2179336.

Fibroblast Growth Factor 21 Attenuates Diabetes-Induced Renal Fibrosis by Negatively Regulating TGF-β-p53-Smad2/3-Mediated Epithelial-to-Mesenchymal Transition via Activation of AKT.

Lin S, Yu L, Ni Y, He L, Weng X, Lu X Diabetes Metab J. 2019; 44(1):158-172.

PMID: 31701691 PMC: 7043973. DOI: 10.4093/dmj.2018.0235.

Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study.

Choi J, Kim J, Park I, Huh J, Kim K, Cha S Yonsei Med J. 2018; 59(2):287-293.

PMID: 29436198 PMC: 5823832. DOI: 10.3349/ymj.2018.59.2.287.

References

Fon Tacer K, L Bookout A, Ding X, Kurosu H, John G, Wang L . Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol. 2010; 24(10):2050-64. PMC: 2954642. DOI: 10.1210/me.2010-0142. View

Zimmet P, Alberti K, Serrano Rios M . [A new international diabetes federation worldwide definition of the metabolic syndrome: the rationale and the results]. Rev Esp Cardiol. 2005; 58(12):1371-6. View

Wissing K, Pipeleers L . Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: prevention and treatment. Transplant Rev (Orlando). 2014; 28(2):37-46. DOI: 10.1016/j.trre.2013.12.004. View

Hardinger K, Koch M, Brennan D . Current and future immunosuppressive strategies in renal transplantation. Pharmacotherapy. 2004; 24(9):1159-76. DOI: 10.1592/phco.24.13.1159.38094. View

de Vries A, Bakker S, van Son W, Homan van der Heide J, Ploeg R, The H . Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant. 2004; 4(10):1675-83. DOI: 10.1111/j.1600-6143.2004.00558.x. View

Reitman M . FGF21: a missing link in the biology of fasting. Cell Metab. 2007; 5(6):405-7. DOI: 10.1016/j.cmet.2007.05.010. View

Ducloux D, Kazory A, Simula-Faivre D, Chalopin J . One-year post-transplant weight gain is a risk factor for graft loss. Am J Transplant. 2005; 5(12):2922-8. DOI: 10.1111/j.1600-6143.2005.01104.x. View

Porrini E, Delgado P, Bigo C, Alvarez A, Cobo M, Checa M . Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis. 2006; 48(1):134-42. DOI: 10.1053/j.ajkd.2006.04.078. View

Bayer N, Cochetti P, Anil Kumar M, Teal V, Huan Y, Doria C . Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation. 2010; 90(8):861-6. PMC: 2959139. DOI: 10.1097/TP.0b013e3181f1543c. View

10.

Eckel R, Grundy S, Zimmet P . The metabolic syndrome. Lancet. 2005; 365(9468):1415-28. DOI: 10.1016/S0140-6736(05)66378-7. View

11.

Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X . Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 2010; 53(5):934-40. DOI: 10.1016/j.jhep.2010.05.018. View

12.

Ford E, Giles W, Mokdad A . Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care. 2004; 27(10):2444-9. DOI: 10.2337/diacare.27.10.2444. View

13.

McKeehan W, Wang F, Kan M . The heparan sulfate-fibroblast growth factor family: diversity of structure and function. Prog Nucleic Acid Res Mol Biol. 1998; 59:135-76. DOI: 10.1016/s0079-6603(08)61031-4. View

14.

Ornitz D, Itoh N . Fibroblast growth factors. Genome Biol. 2001; 2(3):REVIEWS3005. PMC: 138918. DOI: 10.1186/gb-2001-2-3-reviews3005. View

15.

Gorar S, Culha C, Uc Z, Dellal F, Serter R, Aral S . Serum fibroblast growth factor 21 levels in polycystic ovary syndrome. Gynecol Endocrinol. 2010; 26(11):819-26. DOI: 10.3109/09513590.2010.487587. View

16.

Bosma R, Kwakernaak A, van der Heide J, de Jong P, Navis G . Body mass index and glomerular hyperfiltration in renal transplant recipients: cross-sectional analysis and long-term impact. Am J Transplant. 2007; 7(3):645-52. DOI: 10.1111/j.1600-6143.2006.01672.x. View

17.

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

18.

Dushay J, Chui P, Gopalakrishnan G, Varela-Rey M, Crawley M, Fisher F . Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010; 139(2):456-63. PMC: 4862867. DOI: 10.1053/j.gastro.2010.04.054. View

19.

Kharitonenkov A, Wroblewski V, Koester A, Chen Y, Clutinger C, Tigno X . The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 2006; 148(2):774-81. DOI: 10.1210/en.2006-1168. View

20.

Woo Y, Xu A, Wang Y, Lam K . Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol (Oxf). 2012; 78(4):489-96. DOI: 10.1111/cen.12095. View